Appointments: Senior Hires At IGM, Cell Medica, Mologen, Navitor, Tenaya, Oncobiologics, Provention Bio And Centrexion

New CEOs have been appointed at Cell Medica, Mologen, Navitor Pharmaceuticals, Tenaya Therapeutics and Oncobiologics, while a new CMO has been recruited to IGM Biosciences, a vice president of clinical development at Provention Bio and a CFO at Centrexion Therapeutics.

Leading immuno-oncology pioneer, Daniel Chen, has been appointed chief medical officer, a newly created position, at Mountain View, CA-based IGM Biosciences, to lead its clinical development activities. Chen was formerly global head of cancer immunotherapy development at Genentech/Roche. IGM Biosciences, which is evaluating IgM antibodies as therapeutic agents, has also added antibody engineering researcher, William Strohl, to its board of directors.

Cell Medica Ltd., which has offices in London and Houston, has named Chris Nowers as CEO and executive director,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Executives On The Move

Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>

More from Leadership

An Activist Investor Makes A Play For Pfizer

 

Starboard Value has reportedly bought a $1bn stake in Pfizer with an ambition to turn the big pharma around. But growth, not cost cuts, are Pfizer’s challenge.

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>